Bee Vectoring Technologies International Inc. announced significant Research and Development advancements for its proprietary biological control agent Clonostachys rosea strain CR-7 (CR-7) use as a seed treatment solution for soybeans. This breakthrough underscores the product's compatibility and safety on seeds, propelling it toward commercialization in the agriculture sector. The seed treatment market is a significant new revenue opportunity for the Company.

Through a future Research highlights include: Extended Viability: CR-7 demonstrates a long shelf life once it is coated on soybean seeds. This is a key metric for seed treatments since seeds may not be planted for 6-12 months post- treatment, thus giving BVT sales partners a strong value proposition and a robust product. This shelf-life study in ongoing.

Compatibility with other seed treatments: Testing confirms CR-7's compatibility with other seed treatment products, including biologicals and chemical pesticides, ensuring it fits seamlessly into existing agricultural practices where multiple products are applied to the seed at the same time. Proven Safety: Extensive safety tests show that CR-7 does not harm soybean plant germination or growth, maintaining plant health from seed through maturity. Additional observations from BVT's R&D team included: No observation of negative interactions between CR-7 and other microbes.

CR-7 demonstrated significant compatibility with a number of major and commonly used fungicides. After nine months, CR-7 remains detectable in seedlings, demonstrating that it stays dormant until activated by a live host. This underscores its robust and enduring shelf life.